【摘要】 目的 通过利培酮治疗中国精神分裂症患者多中心开放性研究,进一步验证利培酮的疗效及安全性。方法 入组对象为符合DSM—Ⅳ及CCMD—2—R精神分裂症诊断标准的患者。213例完成为期8周的观察,其中男性117例,女性96例,平均年龄为30.9±8.6岁。利培酮平均治疗剂量为4.8±1.2mg/d。在治疗前及治疗后1、2、4、6及8周分别评定PANSS及CGI量表,在治疗前及治疗后1、4及8周评定ESRS量表。结果 利培酮总有效率为74.6％,显效率为17.4％。PANSS总分、阳性症状因子分、阴性症状因子分及一般病理症状分,治疗前后相比均有极显著差异。利培酮起效快,治疗剂量低。利培酮较安全,常见副反应有锥外系副反应(22.5％～15.0％)及失眠(21.6％),而窦性心动过速、ALT(或AST)升高、焦虑、流涎、头昏、头痛等副反应发生率较低。结论 利培酮是一种较理想的抗精神病药物,对阳性症状及阴性症状均有效,起效快,治疗剂量低,安全性高。患者对该药的耐受性及依从性好。可作为精神分裂症的首选药物之一。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of risperidone in the treatment of Chinese schizophrenic patients. Methods 213 cases of schizophrenia inpatients in 11 clinic ceniers were treaied openly with risperidone (4. 8±1. 2 mg/d) for 8 weeks. PANSS, CGI, and ESRS scales were rated before and after treatment regularly. Results Responsive rate of the treatment (decrement of rating score >60%) was 17. 4% , while the rate of decrement >40% was 74. 6%. Common side effects were exirapyramidal symptoms (22. 5%) and insomnia (21. 6%). Conclusion Risperidone is an ideal new antipsychotic drug for the treatment of schizophrenia with good effioaoy. low dosage, and less side effects.更多还原